GHK-Cu vs AHK-Cu

Published August 2026 · Patriot Labs Research Team · ~11 min read

There are two copper tripeptides in common circulation, and they are almost the same molecule. GHK-Cu is glycine–histidine–lysine carrying a copper(II) ion. AHK-Cu is alanine–histidine–lysine carrying a copper(II) ion. Swap the glycine at position one for alanine — which is glycine with a methyl group attached — and one becomes the other.

In cosmetic ingredient nomenclature the two are distinguished as copper tripeptide-1 (GHK-Cu) and copper tripeptide-3 (AHK-Cu). Those names are worth knowing because they are how the compounds appear in formulation literature and ingredient lists, where the peptide abbreviations rarely show up.

The honest summary of the comparison is this: the chemistry is nearly identical and the evidence base is not remotely comparable. Everything else in this guide is elaboration on that sentence. If you want the full coordination chemistry, our AHK-Cu deep dive works through it in detail, and the GHK-Cu explainer covers the better-known half of the pair. This page is the map that sits between them.

One methyl group apart

Copper peptides work because a short peptide chain can wrap a copper ion in a defined chemical grip. In GHK-Cu, which has been characterised in detail, the copper is held by three donor atoms along the backbone: the imidazole nitrogen of the histidine side chain, the alpha-amino nitrogen at the N-terminus, and the deprotonated amide nitrogen of the peptide bond between residues one and two. A carboxyl oxygen from a neighbouring complex can complete a square-planar-pyramidal geometry.

AHK-Cu has every one of those features. The N-terminus is still free, histidine is still at position two supplying the imidazole, and the amide nitrogen between the first two residues is still there. A free N-terminal amine with a histidine at position two or three is a recognised high-affinity copper motif in peptide chemistry, and substituting alanine for glycine does not remove a single donor atom. Structurally, the two molecules bind copper the same way.

What changes is a methyl group sitting on the alpha carbon of residue one — directly adjacent to the coordination site. That is a small addition, but small is not the same as irrelevant: it adds steric bulk and a little hydrophobicity right where the metal is held, and it makes AHK a non-natural sequence in a way GHK is not.

Here is the part that gets glossed over. GHK-Cu has a reported stability constant of log₁₀ = 16.44, set against 8.68 for the simpler glycyl-histidine copper complex — nearly eight orders of magnitude gained from one additional residue and one additional anchor point. That figure is specific to GHK-Cu. We were not able to locate an equivalently rigorous published constant for AHK-Cu. The defensible statement is that AHK-Cu binds copper through the same structural motif; the precise affinity is not a number anyone should be quoting for it.

This matters more than it sounds. Binding affinity determines whether a complex survives contact with the other copper-binding species it meets — serum albumin, amino acids, media components. Assuming a shared motif implies a shared constant is exactly the kind of shortcut that turns into a citation chain nobody ever checks.

What the copper is actually for

Both compounds exist because of the metal, not the peptide alone. Copper is a mandatory cofactor for a set of enzymes with no substitute, and the list explains most of the research interest in copper peptides as a class.

• Lysyl oxidase — required for the cross-linking of collagen and elastin fibres, which is what gives connective tissue its combination of strength and flexibility. This is the mechanistic thread that connects copper to extracellular matrix research.
• Cytochrome c oxidase — the terminal enzyme of the respiratory chain, reducing molecular oxygen to water and generating the gradient that drives ATP production.
• Copper/zinc superoxide dismutase — converts superoxide to hydrogen peroxide, a front-line antioxidant enzyme present in most cells.
• Tyrosinase — required for melanin biosynthesis in melanocytes, and therefore for normal pigmentation of hair, skin and eyes.
• Ceruloplasmin — a multi-copper oxidase that oxidises ferrous iron so it can bind transferrin, tying copper handling to iron handling.

Copper availability is not a peripheral detail in connective tissue biology. It is load-bearing, and it is the same for both tripeptides — neither one has a monopoly on the metal it carries.

Why chelated copper, not a copper salt

The obvious question: if the interest is in copper, why not study copper sulfate and skip the peptide? Three reasons, and they apply equally to GHK-Cu and AHK-Cu.

Free copper is a pro-oxidant. The same redox flexibility that makes copper useful to enzymes makes the loose ion damaging — ionic copper drives free-radical chemistry, which is why biology essentially never lets copper travel unaccompanied. It is handed between proteins and small molecules that hold it in tightly defined coordination environments. A copper tripeptide is a synthetic version of the same idea.

Defined stoichiometry. A 1:1 peptide-to-copper complex is a single characterised chemical entity. A copper salt dropped into a protein-containing medium is a distribution of species binding opportunistically to whatever is available. One of those is a variable you control.

Different disposition. A small organic complex does not partition, cross membranes or meet transporters the way a solvated metal ion does. Whether that produces meaningfully different delivery is understudied for AHK-Cu specifically, but it is the mechanistic premise the whole field rests on.

Head to head

The specification-level comparison, with the uncertainty left visible rather than smoothed over:

Where the two actually diverge

Structure is a near-tie. Literature is not, and this is the comparison that should drive any decision between the two.

GHK was identified as a human peptide and has accumulated roughly five decades of published work. It is present in plasma at around 200 ng/mL in young adults and declines to about 80 ng/mL by age 60 — a decline that is itself the reason the peptide keeps appearing in anti-aging research discussions. Its sequence occurs in the alpha 2(I) chain of type I collagen, where it becomes available through proteolytic breakdown during injury, giving a plausible account of where endogenous GHK comes from. The modern literature spans wound-healing models, extracellular matrix remodeling, antioxidant gene expression and broad transcriptome analysis — one gene-expression review reports GHK modulating a large fraction of human genes at a 50% change threshold, increasing expression in roughly 59% of affected genes and suppressing it in 41%.

AHK-Cu is a different situation entirely. Nearly everything written about it traces to one paper: Pyo, Yoo and colleagues, Archives of Pharmacal Research, 2007. That study applied AHK-Cu across 10⁻¹² to 10⁻⁹ M in two models — ex vivo human hair follicle organ culture and cultured dermal papilla cells — and reported that it stimulated follicle elongation and dermal papilla cell proliferation, with an elevated Bcl-2/Bax ratio and reduced cleaved caspase-3 and cleaved PARP. It also reported, and this is the bullet that rarely survives into secondary write-ups, that the reduction in apoptotic dermal papilla cells measured by flow cytometry was not statistically significant. The authors' own conclusion used the word “may.”

To put a number on the gap: as of August 2026, a Europe PMC literature search for the term “AHK-Cu” returns five records in total, of which one is the 2007 primary study and the rest are reviews, formulation papers or studies where the compound appears incidentally. A recent review of short peptides for hair loss mentions AHK-Cu once, in a single sentence crediting the 2007 result.

The “skin one and hair one” framing

The most common way these two get sold against each other is the neat split: GHK-Cu is the skin peptide, AHK-Cu is the hair peptide. It is memorable, it is easy to write product copy around, and it is not supported.

What the literature actually shows is where the studies were pointed. The AHK-Cu work happened in follicle models because the group that ran it was studying hair. The GHK-Cu literature is broader because far more groups have worked on it, across more tissues, for longer. Neither of those facts is a measurement of tissue selectivity.

Demonstrating selectivity would require the head-to-head experiments nobody has published: both compounds, matched concentrations, the same skin and follicle models, run in parallel. Absent that, “AHK-Cu is the hair one” is a statement about a bibliography, not about biology. It is also worth noting that GHK-Cu itself appears in hair research, which the tidy split quietly ignores.

The version that survives scrutiny: the AHK-Cu literature is concentrated on follicle models, the GHK-Cu literature is much broader and much deeper, and no comparative data exists that would let anyone claim either molecule prefers a tissue.

What the evidence does not establish

This section matters more than the tables above it.

That the methyl group does anything. Nobody has published the direct comparison that would settle whether replacing glycine with alanine changes copper affinity, cellular uptake, stability or activity. The molecules are structurally near-identical and the temptation is to assume they are functionally interchangeable — but that assumption is untested in either direction. Both “they are basically the same” and “they do different things” are currently claims without data.

That AHK-Cu's copper affinity resembles GHK-Cu's. The log₁₀ 16.44 figure belongs to GHK-Cu. Transplanting it is an assumption dressed as a citation.

That either finding transfers out of its model. An ex vivo follicle has no circulation, no hormonal input, no immune system and no nervous system. Cultured dermal papilla cells are a further step removed and are known to drift in behaviour over successive passages. Rodent wound-healing models are informative and are not people. None of this is a criticism of the studies — it is what the models are for.

That the peptide rather than the copper is responsible. If a copper complex produces an effect, disentangling the ligand from the metal requires apo-peptide controls, matched copper-salt controls and an inactive chelator. That control set is not established in the AHK-Cu record. Any confident statement that the activity is a property of the AHK sequence is running ahead of the evidence.

That picomolar activity is a settled result. Effects reported at 10⁻¹² M are striking, and they also sit in a range where copper carried in by serum, trace contamination and small pipetting errors are proportionally large. Low-concentration findings raise the bar for controls and replication rather than lowering it.

That any of this describes an outcome in a person. Nothing in this comparison speaks to human use. Both compounds are research materials.

Practical differences at the bench

Handling requirements are essentially identical, because they follow from the copper rather than the sequence. Both are coloured Cu(II) complexes, both are antagonised by strong reducing agents such as ascorbic acid, both depend on a deprotonated amide nitrogen and are therefore pH-sensitive, and both will lose their metal to competing chelators like EDTA. Our AHK-Cu guide works through those points in detail and they apply unchanged to GHK-Cu. General storage practice and reconstitution practice still apply on top.

The one genuinely comparison-specific point is identity confirmation. AHK and GHK differ by 14 mass units — a single methyl group. That is trivial for a mass spectrometer and impossible by eye, and both materials are blue powders that reconstitute into blue solutions. If a protocol depends on which one is in the vial, the certificate of analysis is the only place that question gets answered. Check that the COA is traceable to the specific lot in hand, and that the mass spectrometry reflects the copper complex rather than the free peptide.

The other practical consideration is availability. GHK-Cu is stocked as a standalone and also appears as a component of the Glow blend alongside BPC-157 and TB-500, and in KLOW. AHK-Cu is supplied on its own and is currently out of stock. That asymmetry is itself downstream of the evidence gap — the better-documented molecule is the one that ends up in multi-component research blends.

Frequently asked questions

What is the difference between GHK-Cu and AHK-Cu? One amino acid. GHK is glycine–histidine–lysine, AHK is alanine–histidine–lysine, and alanine is glycine plus a methyl group. Both carry copper(II) through the same three-point coordination motif.

Why do they have different INCI names? Because they are different chemical entities in ingredient nomenclature: GHK-Cu is copper tripeptide-1 and AHK-Cu is copper tripeptide-3. The numbering reflects registration order, not potency or generation.

Is GHK-Cu for skin and AHK-Cu for hair? No — that split describes where the studies happened to be pointed, not demonstrated tissue selectivity. The comparative experiments that would justify it have not been published.

Which one has more research behind it? GHK-Cu, decisively. It occurs naturally in human plasma, its sequence appears in type I collagen, its level declines with age, and it has decades of literature. AHK-Cu is dominated by a single 2007 study.

Do they bind copper equally tightly? Unknown. GHK-Cu has a reported stability constant of log₁₀ = 16.44; no comparable published figure for AHK-Cu could be located, and the shared motif does not license borrowing the number.

Can they be told apart visually? No. Both are blue Cu(II) complexes and differ by 14 mass units. Mass spectrometry on a lot-traceable COA is the only reliable check.

Are they approved for human use? No. Both are sold strictly for in-vitro research and laboratory use only, and neither is intended for human or veterinary consumption.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.